The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: A 12 month cohort study in Harare, Zimbabwe by Dimairo, M. et al.
The Risk and Timing of Tuberculosis Diagnosed in
Smear-Negative TB Suspects: A 12 Month Cohort Study
in Harare, Zimbabwe
Munyaradzi Dimairo1, Peter MacPherson2*, Tsitsi Bandason1, Abbas Zezai1, Shungu S. Munyati1,
Anthony E. Butterworth3, Stanley Mungofa4, Simba Rusikaniko5, Katherine Fielding6, Peter R Mason1,
Elizabeth L. Corbett3
1 Biomedical Research and Training Institute, Harare, Zimbabwe, 2Wellcome Trust Tropical Centre, University of Liverpool, Liverpool, United Kingdom, 3Clinical Research
Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4Harare City Health, Harare, Zimbabwe, 5University of Zimbabwe College of Health
Sciences, Harare, Zimbabwe, 6 Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract
Background: Cases of smear-negative TB have increased dramatically in high prevalence HIV settings and pose considerable
diagnostic and management challenges.
Methods and Findings: Between February 2006 and July 2007, a cohort study nested within a cluster-randomised trial of
community-based case finding strategies for TB in Harare, Zimbabwe was undertaken. Participants who had negative
sputum smears and remained symptomatic of TB were follow-up for one year with standardised investigations including
HIV testing, repeat sputum smears, TB culture and chest radiography. Defaulters were actively traced to the community. The
objectives were to investigate the incidence and risk factors for TB. TB was diagnosed in 218 (18.2%) participants, of which
39.4% was bacteriologically confirmed. Most cases (84.2%) were diagnosed within 3 months, but TB incidence remained
high thereafter (111.3 per 1000 person-years, 95% CI: 86.6 to 146.3). HIV prevalence was 63.3%, and HIV-infected individuals
had a 3.5-fold higher risk of tuberculosis than HIV-negative individuals.
Conclusion: We found that diagnosis of TB was insensitive and slow, even with early radiography and culture. Until more
sensitive and rapid diagnostic tests become widely available, a much more proactive and integrated approach towards
prompt initiation of ART, ideally from within TB clinics and without waiting for TB to be excluded, is needed to minimise the
risk and consequences of diagnostic delay.
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Introduction
Southern Africa has experienced steeply rising TB incidence
rates driven by the HIV epidemic, and now carries over three-
quarters of the global burden of HIV-positive TB cases [1,2]. In
many high HIV prevalence countries the most striking increase
has been in smear-negative TB cases [1].
In resource poor settings, smear-negative TB is difficult to
diagnose and also difficult to exclude, especially in HIV-infected
patients [3,4]. Case series and post-mortem studies have shown the
diagnosis of smear-negative TB to be highly specific [5]. However,
the mounting evidence of low sensitivity of smear microscopy [6]
and the high mortality, loss to follow-up and rate at which clinical
deterioration occurs during diagnostic work up of HIV-positive
smear negative TB suspects [7,8] prompted a recent change in
international management guidelines. In 2007, new guidelines [9]
for use in settings with generalised HIV epidemics promoted
diagnostic HIV testing of TB suspects, earlier use of radiography,
increased access to sputum culture, a lower threshold for starting
TB treatment in HIV-infected patients, and greater recognition of
the symptoms of extra-pulmonary and disseminated TB (such as
rapid weight loss and night sweats) in addition to chronic cough.
For ambulant patients, a routine trial of broad-spectrum
antibiotics in TB suspects was not recommended under these
guidelines, but the need to exercise ‘‘clinical judgement’’ before
starting TB treatment was retained.
We applied a standardised diagnostic protocol that predated but
shared several key features of the new WHO guidelines, including
early use of culture and chest radiography to a cohort of smear-
negative TB suspects identified through a community-based
intervention in Harare, Zimbabwe, who were then followed up
for one year with active tracing of defaulters. The aims of the study
were to investigate whether or not TB suspects had a high
incidence of being diagnosed with TB in the year following initial
work-up, suggesting missed diagnosis, and to investigate the role of
routine culture in the diagnosis of smear-negative TB. Access to
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antiretroviral therapy (ART) was through the public health care
system in Harare.
Methods
This was a cohort study nested within a cluster randomised trial
investigating two strategies (household enquiry vs. self-referral to a
mobile community clinic) of community-based intensified case
finding for TB in an urban community with a high prevalence of
TB and HIV infection (DETECTB) [10].
Ethical Approval
Ethical approval was obtained from the Medical Research
Council of Zimbabwe, the Biomedical and Research and Training
Institute, Harare and the London School of Hygiene and Tropical
Medicine. Written informed consent was obtained from all
participants. All participants were offered diagnostic HIV testing
and counselling, with referral for assessment for ART if positive.
Unreported HIV results taken for study purposes were held under a
dedicated HIV test number, and only linked with other data
through a computer programme that merged files and immediately
dropped all personal identifiers, thus maintaining confidentiality.
Study Setting and Population
Forty-six neighbourhood clusters in Western Harare, Zim-
babwe, were provided with 6-monthly outreach access to TB
microscopy at community-level as part of a cluster-randomised
trial. The cohort reported here was drawn from participants in the
cluster-randomised trial and who were recruited between
February 2006 and June 2007. Inclusion criteria for the nested
cohort study were: age 16 year or older; underwent outreach
screening for TB in the community; had two negative sputum
smears (morning and spot specimens); had ongoing symptoms of:
cough; or weight-loss; night sweats; or a history of haemoptysis
within the last year; and returned to take up our offer of follow-up
investigations at the study clinic situated in a TB and HIV
treatment facility.
Initial Assessment for TB and HIV Testing
On first presentation at the TB and HIV clinic, initial
assessment included recording of TB symptoms chest radiography,
repeat morning and spot sputum smears and TB culture; and
treatment with seven days of broad-spectrum antibiotics (amox-
icillin). Participants with radiological features strongly suggestive of
TB (including pleural or pericardial effusion) were referred for
immediate TB treatment [9].
Additionally, on first assessment, all participants were asked to
consent to provide an HIV specimen for study purposes and were
advised to have diagnostic HIV testing and counselling (HTC),
provided initially through routine testing and counselling services,
and later through diagnostic HIV testing within the study clinic.
HIV-positive participants were prescribed cotrimoxazole prophy-
laxis and referred to the adjacent public ART clinic where
initiation criteria were CD4 count of #200 cells/ul, or a WHO
stage 4 illness. From May 2006 all participants accepting
diagnostic HTC also had blood taken for CD4 count.
Participants who declined diagnostic HIV testing were asked
for consent to provide a specimen for HIV testing for study
purposes.
Follow-up Procedures
Follow-up review for participants who were clinically stable was
undertaken at the TB and HIV clinic 1, 8 and 12 months after
initial assessment. Participants were advised to attend for
unscheduled assessment and management if they became unwell.
During follow-up assessments, participants underwent repeat
assessment of symptoms and submitted further samples for sputum
smear and TB culture. Chest x-ray was repeated if the participant
was coughing. Participants with positive smears or cultures, with
symptoms that did not respond to antibiotics, or with radiological
signs of TB were referred for TB treatment. Participants who did
not return for scheduled visits were followed-up at their home
address.
Participants started on TB treatment were followed up at 1,8
and 12 months after commencing TB treatment. The 8 months
review was chosen to allow assessment of TB treatment outcomes.
Case Definitions for Diagnosis of TB
A confirmed TB case was defined as a positive smear (including
scanty positive) or one or more positive cultures for M. tuberculosis.
Smear- and culture-negative TB was defined by a clinical or
radiological illness consistent with TB that did not respond to
broad-spectrum antibiotics but did respond to one month of anti-
tuberculosis treatment, or where TB treatment was started
independently by an outside provider. Participants were classified
as lost-to-follow-up if they did not attend for review (scheduled or
unscheduled) during the study period and could not be traced.
Laboratory Methods
Microbiology work was undertaken at the Biomedical and
Research Training Institute, Harare, Zimbabwe. Smears were
made from concentrated decontaminated (4% NaOH) specimens
and read by fluorescence microscopy after staining with auramine-
O. Positives were confirmed with Ziehl-Neelsen staining. Culture
used Lowenstein-Jensen (LJ) slopes. Species were classified as
M.tuberculosis or non-tuberculous mycobacteria according to colony
morphology, microscopic cording, ability to grow on PNB-
containing LJ media, and growth at 45uC, 37uC and room
temperature. From 2008, MBP84 lateral flow assays for rapid
species identification were also used.
Diagnostic HIV testing was offered with pre-and post test
counselling (parallel testing with DetermineTM HIV-1/2, Abbott
Japan, Inverness Medical Japan, Tokyo, Japan and Uni-Gold
RecombigenH, Trinity Biotech, Dublin, Ireland); unreported study
HIV tests used serial testing (Abbott DetermineTM with all
positives and 10% of negatives confirmed by Uni-Gold Recombi-
genH) or oral mucosal transudate from participants not willing to
provide serum, tested using VironostikaH Uni- form II (BioMe´r-
ieux, Marcy l’Etoile, France).
Statistical Analysis
We investigated TB free survival time from first clinical
assessment to the earliest of last clinical review date, date of TB
diagnosis or date of death. Incidence rates for outcomes were
calculated using the Poisson distribution. Eight confirmed TB
cases had missing data for date of TB diagnosis and so multiple
imputation using chained equations, taking into account potential
clustering, was used in these cases [11].
Baseline characteristics of participants were expressed as
proportions and compared by HIV status using Fisher’s exact
test. We used Cox proportional hazard regression to assess the
association of sex, age, weight, CD4 count and previous TB
treatment with TB free survival, stratified by HIV status.
Knowledge of HIV-status was not included due to high collinearity
with unknown CD4 count category. Plots of Schoenfeld residuals
were inspected to ensure the validity of the proportional hazards
assumptions.
Outcomes of TB Suspects
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Data management and analysis was conducted using EpiInfo
2003 (CDC, Atlanta) and STATA 10.1 (College Station, Texas,
USA).
Results
Baseline characteristics and follow-up
Between February 21, 2006 and June 6 2007, 5731 adults
participated in the cluster-randomised parent study, and had two
negative sputum smears. All participants in the parent study were
provided with a clinic appointment card that could be used to
obtain further investigations if smears were negative: 1,234
(21.5%) took up this opportunity and so form the starting cohort
of this study (Figure 1). Thirty-nine (3.2%) participants were
excluded from this analysis: 15 (1.2%) had missing baseline
information and 24 (1.9%) did not attend any subsequent review
after their initial appointment, leaving 1195 participants who were
smear-negative TB suspects in this analysis (Figure 1). During the
12-month study period, 170 (14.2%) cohort participants were lost
to follow-up. As reported separately, mortality rates were high with
97 participants dying without a diagnosis of TB and a further 42
participants dying after TB was diagnosed giving a total of 139
(11.6%) deaths during the study period (122.3 per 1000 person-
years (95% CI: 104.4 to 144.3).
A total of 1143 participants underwent HIV testing with a
further 52 (4.4%) refusing. Among participants who tested HIV-
positive, 494 (68.3%) accepted diagnostic HIV testing and
counselling (HTC) and 229 (31.7%) declined HTC but gave
samples for unreported study testing. HIV prevalence was 63.3%.
Baseline characteristics of HIV-positive and HIV-negative partic-
ipants are shown in Table 1. HIV-positive participants were more
likely than HIV-negative participants to be female (p = 0.019), and
to have previously been treated for TB (p,0.001). They were also
more highly symptomatic, with breathlessness at rest the only one
of 12 considered symptoms that was not significantly more
prevalent than in HIV-negative participants. Median CD4 count
(limited to those accepting diagnostic HTC after May 2006: see
Methods) was 149 (IQR 69 to 255) cells/ul: only 15.3% of counts
were above 350 cells/ul, with a further 21.7% between 200 and
350 cells/ul.
TB cases diagnosed during follow-up
From the 1195 participants, 218 (18.2%) TB cases were
diagnosed in 1051.2 person-years of follow-up (Table 2). Eighty-
six (39.4%) had confirmed TB and 127 (58.3%) were smear- and
culture-negative. Five (2.3%) participants were treated for TB
without clinical response, so failing to meet study case-definitions.
HIV prevalence was 83.5% (95% CI: 77.8 to 88.2%) in
participants diagnosed with TB.
Early (within 3 months) TB diagnoses
TB free survival stratified by HIV status is shown in Figure 2.
The majority of TB cases (139, 63.8%) were identified in the early
period (0–3 months), and so are likely to represent prevalent
disease at cohort entry. One hundred and seventeen (84.2%) of the
participants diagnosed between 0 to 3 months were HIV-positive.
HIV-stratified TB incidence within the first 3 months was 705.9
(95% CI: 580.8 to 860.2) and 205.0 (95% CI: 123.9 to 364.2) per
1000 person-years for HIV-positive and- negative participants
respectively.
Late (3 to 12 months) TB diagnoses
Between 3 and 12 months of follow-up, a further 79/218
(36.2%) TB cases were diagnosed. Incidence rates for this time
period were 111.3 per 1000 person-years (95% CI: 86.6 to 146.3)
in HIV-positive participants and 31.3 per 1000 person years (95%
CI: 19.7 to 53.1) in HIV negative participants.
Bacteriologically confirmed disease was diagnosed more fre-
quently amongst participants diagnosed with TB within the first 3
months (60/139; 43.2%) compared with participants diagnosed in
the subsequent 9 months of follow-up (26/79; 32.9%; p= 0.151).
HIV Positive Participants
51/117 (43.6%) had bacteriologically confirmed TB diagnosed
within the first 3 months compared to only 16/65 (36.8%) in the
subsequent 9 months (odds ratio (OR)= 2.4, 95% CI: 1.2 to 4.6;
p = 0.016) in HIV positives individuals.
HIV Negatives Participants
8/21 (38.1%) had bacteriologically confirmed TB diagnosed
within the first 3 months compared to 9/13 (69.2%) in the
subsequent 9 months (OR=0.3, 95% CI: 0.1 to 1.2; p = 0.157) in
HIV negatives participants.
Delay in Diagnosis of TB
Median delay in diagnosis of bacteriologically confirmed and
smear- and-culture negative disease TB was 2.0 (IQR: 1.2 to 3.4)
months and 2.3 (1.5 to 5.4) months, respectively. HIV-negative
participants had a longer delay in diagnosis of bacteriologically
confirmed TB (3.1 months, IQR: 2.0 to 5.5) than HIV-positive
(1.9 months, IQR: 1.1 to 3.0; p = 0.04), but similar delay to
diagnosis of smear- and culture-negative TB (HIV-positive = 2.3
months IQR: 1.5 to 6.0; HIV-negative = 2.3 months IQR: 1.6 to
2.8; p = 0.61).
Risk Factors for TB Diagnosis
HIV infection was the predominant risk factor for TB diagnosis,
with TB incidence 3.5 times higher in HIV-positive participants
(incidence 311.6 per 1000 person years, 95% CI: 266.7 to 364.9)
compared to HIV-negative participants (incidence 81.8 per 1000
person-years, 95% CI: 58.3 to 118.2).
In univariable analysis among HIV-positive participants
(Table 3), low weight (hazard ratio (HR): 2.11, 95% CI: 1.19 to
3.74) and CD4 count between 50 and 100 cells/ul (HR: 1.68, 95%
CI: 1.08 to 2.62) were associated with an increased hazard of
incident TB, while female sex showed a reduced hazard of TB
(HR: 0.71, 95% CI: 0.50 to 1.01). These associations remained
on multivariable analysis. On adjusted analysis there was an
association between trend towards low CD4 count (pt = 0.024), low
weight (pt = 0.026) and TB diagnosis. Among HIV-negative
participants (Table 4), factors associated with a TB diagnosis in
both univariable and multivariable analysis were a history of past
TB treatment (adjusted hazard ratio (aHR): 2.18, 95% CI: 1.04 to
4.57), and older age (aHR: 2.07 [95% CI 0.88–4.89] for 35–45
years, 2.47 [95% CI: 1.22 to 5.02] for .45 years compared
with ,35 years).
Outcomes of TB Treatment
Two hundred and fourteen of 218 participants diagnosed with
TB were started on TB treatment (4 were lost to follow-up in the
interim) and followed for treatment outcomes. Ten participants
defaulted from TB treatment and 10 were transferred out.
Treatment completion rates were 69.6% (126/182) for HIV-
positive and 75.0% (24/32) for HIV-negative participants, with
case-fatality rates higher among HIV-positive (21.5%: 39 deaths
on treatment) than HIV-negative (9.4%: 3 deaths, p,0.001)
participants.
Outcomes of TB Suspects
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Uptake of ART
Although 494 (68.3%) of the HIV-positive participants
accepted diagnostic HTC and were referred for ART, only
106 (20.9% of those referred and 14.7% of all HIV positive
participants) were started on ART during the 12-month follow-
up. 145 (37.0%) of patients with known CD4 counts did not meet
the ART initiation criteria (CD4 count of #200 cells/ul or
WHO stage 4 illness), and limited availability of ART in the
Zimbabwean public health care system was also a major
constraint. Median time between TB diagnosis and ART
Figure 1. Cohort Flowchart. Diagnostic outcomes of smear negative TB suspects. LTFU: Lost to follow-up before TB diagnosis or in participant
without TB diagnosed.
doi:10.1371/journal.pone.0011849.g001
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initiation was 2.7 months (IQR: 1.1–7.1) and between study
enrolment and ART initiation in those in whom TB was not
diagnosed was 3.0 (IQR; 2.0 to 4.3) months.
Discussion
The main finding from this large cohort of smear-negative
TB suspects is the high incidence of TB diagnoses throughout
12 months of follow-up, for both HIV-positive and HIV-
negative participants. HIV infection increased the risk of
TB substantially in both early (within 3 months) and later
periods.
In this cohort low weight and CD4 counts below 200 cells/ul
were the main risk factors for subsequent diagnosis of HIV-related
TB, while older age and past history of TB treatment were risk
factors for HIV-negative TB. Past TB was a strong risk factor for
recurrent disease in HIV-negative, but not HIV-positive, partic-
ipants. This difference probably reflects the high susceptibility to
rapid progression following re-infection with M.tuberculosis in HIV-
positive individuals [12,13].
TB was confirmed microbiologically in only 39.4% of TB
cases, despite routine solid media culture for all TB suspects.
With advanced HIV disease, sputum smears are more likely to
be negative [14] and chest radiography may be normal [15].
Other studies from high HIV prevalence settings using
combined clinical and bacteriological case-definitions and
not restricted to smear-negative suspects have reported
between 10% and 45% of patients as culture-negative [16–
18]. The high rates of late diagnoses and low rates of culture-
confirmed TB implies that diagnosing smear-negative TB
Table 1. Baseline characteristics and symptoms of smear-negative TB suspects by HIV status.
Characteristic Scoring HIV+ (%) HIV2 (%) P
Total* 723 (63.3) 420 (36.8)
Sex Female 470 (65.0) 243 (57.9) 0.019
Male 253 (35.0) 177 (42.1)
Age (years) Median (IQR) 36 (30.0 to 42.0) 39 (30.0 to 54.0)
,25 60 (8.3) 47 (11.2)
25–34 261 (36.1) 111 (26.4) ,0.001
35–45 264 (36.5) 95 (22.6)
.45 138 (19.1) 167 (39.8)
CD4 count (cells/ul) (391 patients) Median (IQR) 149 (69 to 255) -
0–#50 78 (19.9) -
50–#100 60 (15.3) -
100–#200 108 (27.6) -
200–#350 85 (21.7) -
.350 60 (15.3)
Previous TB treatment Yes 138 (19.1) 35 (8.3) ,0.001
Chest x-ray: attending clinician classification Normal 219 (30.8) 167 (39.8) ,0.001
Typical of TB 27 (3.7) 7 (1.7)
Atypical abnormality, but consistent with TB 275 (38.0) 93 (22.1)
Suggests an alternative (non-TB) diagnosis 18 (2.5) 18 (4.3)
Not done 184 (25.5) 135 (32.1)
Symptoms
Cough greater than 3 weeks Yes 543 (75.1) 263 (62.6) ,0.001
Sputum Yes 401 (55.5) 168 (40.0) ,0.001
Purulent sputum Yes 313 (43.3) 123 (29.3) ,0.001
Blood in sputum Yes 145 (20.1) 37 (8.8) ,0.001
Duration with TB symptoms (weeks) Median (IQR) 11.5 (4.0 to 20.0) 12 (4.0 to 24.0) –
Chest pain Yes 332 (45.9) 155 (36.9) ,0.001
Pleuritic painful cough Yes 208 (28.8) 100 (23.8) ,0.001
Exertional dyspnoea Yes 400 (55.3) 184 (43.8) ,0.001
Dyspnoea at rest Yes 92 (12.7) 38 (9.0) 0.066
Night sweats Yes 447 (61.8) 228 (54.3) 0.015
Change sheets or bedclothes due to sweats Yes 326 (45.1) 127 (30.2) ,0.001
Recent weight loss Yes 557 (77.0) 231 (55.0) ,0.001
Respiratory rate.20 breaths per minute Yes 403 (55.7) 217 (51.6) 0.174
*HIV status not known for 52 (4.4%) participants.
IQR: Interquartile range, HIV+: HIV positive, HIV2: HIV negative.
doi:10.1371/journal.pone.0011849.t001
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remains problematic even with access to culture and early
radiography [9].
We cannot distinguish between three explanations for the high
TB incidence in the later period: a) that culture failed to detect
true smear-negative TB initially, or b) misdiagnosis of other (non-
TB) conditions as TB, or c) a high incidence of new TB during
follow-up. But, given the consistent autopsy findings that
disseminated TB is frequently missed in HIV-infected patients
Table 2. TB cases diagnosed during study period.
TB case definition Total* (n =218) HIV+ (n =182) HIV2 (n = 34)
n (% of cases) n (%) n (%)
Bacteriology confirmed{ 86 (39.4) 67 (36.8) 17 (50.0)
Time to diagnosis
0 to 3 months: 60 (69.8) 51 (76.1) 8 (47.1)
.3 to 12 months: 26 (30.2) 16 (23.9) 9 (52.9)
Smear- and culture-negative{ 127 (58.3) 110 (60.4) 17 (50.0)
Type of diagnosis
Chest x-ray abnormal: 115 (90.6) 101 (91.8) 14 (82.4)
Clinical: 12 (9.4) 9 (8.2) 3(17.6)
Time to diagnosis:
0 to 3 months 76 (59.8) 63 (57.3) 13 (76.5)
.3 to 12 months 51 (40.2) 47 (42.7) 4 (23.5)
Case definition not met1 5 (2.3) 5 (2.7) 0 (0.0)
*2 patients with TB declined HIV testing, both with smear- and culture-negative disease.
{83 Pulmonary TB, 3 pleural TB.
{105 Pulmonary TB, 9 pleural TB, 4 miliary, 6 other extra-pulmonary TB (ETB), 1 combined ETB and PTB, 2 not classified.
1Treated for TB but case definitions were not met due to lack of response to treatment (4 pulmonary TB, 1 pleural TB).
HIV+: HIV positive, HIV2: HIV negative.
doi:10.1371/journal.pone.0011849.t002
Figure 2. TB free survival stratified by HIV status. Kaplan-Meier estimates showing TB-free survival of cohort members stratified by HIV status.
doi:10.1371/journal.pone.0011849.g002
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[19] and that response to TB treatment was documented in all but
a few of our cases, we assume that delayed diagnosis of prevalent
TB was the main contributor.
TB culture is the current international standard for diagnosis
of smear-negative TB [20]. In low-prevalence HIV settings, TB
culture on solid medium is highly sensitive (80–85%) and
specific (98%) [21], although growth is slow (up to six weeks)
and laboratory intensive [22]. In high prevalence HIV settings,
sensitivity may be reduced [23], while the rapid pace at which
HIV-related TB progresses makes waiting for culture results
clinically inappropriate [7]. Liquid culture systems with early
growth indicators provide more rapid and sensitive growth
and could reduce diagnostic delay [3]. Other sensitive rapid
diagnostics have shown great promise when evaluated against
culture [24] but also need be evaluated against culture-negative
disease, as the diagnostic barriers to management of TB suspects
will not be completely resolved until rapid diagnostic methods
with sensitivity approaching 100% become widely available
[22].
By 12 months one quarter of our HIV-positive smear-negative
TB suspects had been diagnosed with TB, highlighting the
challenge that suspected HIV-related TB presents in the context of
ART scale-up. Our finding that, rather than having disease
excluded, participants continued to be diagnosed with TB at high
incidence throughout follow-up supports a move towards starting
ART promptly without allowing TB investigations to cause undue
delay [25].
In this cohort, uptake of ART was extremely low and delayed
despite low CD4 counts in most participants accepting diagnostic
HIV testing. This in part reflects the unique limitations of public
sector HIV care in Zimbabwe at the time, but other African ART
programmes also report long delays between registration and ART
initiation [26].
Based on these results, we suggest two revisions to the current
recommended management of TB suspects. Firstly, lowering the
threshold for TB treatment in HIV-infected TB suspects who do
not have access to immediate ART. This would move away from
the current recommendations of not starting TB treatment unless
TB is considered likely towards prompt initiation of TB treatment
within a few weeks of presentation as a TB suspect where there are
still any clinical signs or symptoms consistent with TB. Inevitably
this will mean more patients started on TB treatment, with some
negative consequences: the specificity of the diagnosis of smear-
negative TB would be reduced. More patients would also be
subjected to the considerable costs and inconvenience of
unnecessary TB treatment.
Table 3. Univariable and multivariable analysis of risk factors associated with TB diagnosis in HIV-positive participants.
TB cases/PYFU Unadjusted HR (95% CI) P-Value Adjusted HR (95% CI) P-Value
Overall (0–12 months) 182/584.1
Sex
Male 74/186.4 1.0 1.00
Female 108/397.7 0.71 (0.50 to 1.01) 0.058 0.66 (0.47 to 0.94) 0.020
Age (years)
,25 18/49.0 1.0 1.00
25–34 68/213.6 0.85 (0.51 to 1.41) 0.94 (0.57 to 1.55)
35–45 69/207.3 0.89 (0.54 to 1.47) 0.98 (0.56 to 1.71)
.45 27/114.2 0.65 (0.32 to 1.32) 0.611 0.73 (0.32 to 1.64) 0.733
Weight (kg)
0–49 47/98.4 2.11 (1.19 to 3.74) 2.05 (1.08 to 3.87)
50–59 79/241.5 1.49 (0.83 to 2.66) 1.35 (0.73 to 2.52)
60–69 40/168.6 1.13 (0.65 to 1.26) 1.08 (0.62 to 1.87)
.70 16/75.6 1.00 0.008 1.00 0.026
CD4 count (cells/ul)
,50 20/45.6 1.41 (0.82 to 2.43) 1.18 (0.69 to 2.01)
50–,100 33/88.6 1.68 (1.08 to 2.62) 1.66 (1.04 to 2.64)
100–,200 31/132.2 1.53 (0.90 to 2.59) 1.43 (0.82 to 2.48)
$200 77/259.6 1.0 0.091* 1.00 0.024*
Unknown 150/473.0 1.19 (0.80 to 1.79) 1.05 (0.68 to 1.62)
Previous TB treatment
No 150 (473.0) 1.0
Yes 32 (111.1) 0.92 (0.59 to 1.42) 0.709
HIV status known{
No 51/214.5 1.0
Yes 131/369.6 1.48 (1.04 to 2.12) 0.065
*Test for Trend.
{Not included in multivariate model due to collinearity with CD4 count unknown category.
HR: hazard ratio; PYFU: person years follow-up; CI: confidence interval.
doi:10.1371/journal.pone.0011849.t003
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In many respects the preferable second alternative is prompt
and early initiation of ART that would serve both a therapeutic
purpose while also providing the means to rapidly confirm or
exclude TB without leaving patients in the dangerous therapeutic
limbo of having neither their confirmed HIV nor their possible TB
treated. HIV is easy to diagnose, and ART ‘‘unmasks’’ TB [8].
Furthermore, a strategy of early ART initiation would ensure TB
suspects are enrolled in structured follow-up where deterioration of
symptoms can be promptly identified and managed. A recent
randomised control trial has highlighted the benefit of early ART
initiation for TB patients [27]. Our proposed strategy will increase
the incidence of immune reconstitution inflammatory syndrome
(IRIS) related to TB [28], especially in patients with advanced
immunosupression [8,29], but the risk of death from unmasking
IRIS is low and likely to be considerably lower than the risk of
death during prolonged clinical observation before ART initiation
[30]. Although mortality may be lowered with this strategy, an
increase in IRIS-related morbidity may be anticipated. This
strategy could improve integration of TB and HIV services, and
the CD4 count profile reported here suggests that ART initiation
is warranted on CD4 count criteria in all but a small minority of
HIV-infected TB suspects.
Uptake of ART by HIV-positive TB patients can be as low as
20% even in well-resourced ART programmes [31] unless careful
attention is paid to avoiding the high costs incurred by multiple
visits to different clinics [32]. This same phenomenon is likely to
apply to TB suspects as well, whereby patients with limited
resources are effectively forced to choose to invest either in
continued TB investigations or in ART access [32,33].
There were a number of limitations to this study. Firstly, as this
cohort was drawn from participants in the parent cluster-
randomised trial who self-presented for clinic assessment, there
may be some differences from individuals in the general
community and parent study who did not present for assessment.
However, the large cohort number and the provision of a
transport voucher to provide costs to access the clinic went some
way towards mitigating this. As discussed, we cannot distinguish
new incident disease from delayed diagnosis of prevalent disease.
Clinic nurses undertaking assessment for TB were not blinded to
participant’s HIV status and this may have influenced their
decision to commence TB treatment.
Over half of diagnoses were not bacteriologically confirmed,
and so may have been incorrect despite documented treatment
response. Our conclusions concerning culture may be less
applicable to liquid than solid culture. Radiographs were read
by attending clinicians, with no attempt beyond a weekly
radiological meeting to monitor accuracy of interpretation, which
is known to be highly subjective. Attempts were made to minimise
bias in commencement of TB treatment by having explicit criteria
for initial of TB treatment. Loss to follow-up was 14.2% in this
cohort and it is possible that some of those who were lost to follow
up in fact had TB, or died. In cohorts of HIV-positive individuals,
mortality rates among those classified as lost to follow up are
known to be as high as 50% [34]. A relatively low proportion of
participants in this study were diagnosed clinically and this may
reflect the use of TB cultures and chest radiology. Despite these
limitations, our findings have important implications for the
clinical management of smear-negative TB suspects in resource-
limited settings.
Conclusions
In conclusion, management of HIV-positive smear-negative
TB suspects remains unsatisfactory when based upon early
culture and radiology and routine HIV care services. Unless
careful attention is paid to ensuring integrated and timely
access to ART, patients may find themselves caught between
programmes with signs and symptoms that are insufficient to
prompt a clinical decision to start TB treatment, but are
sufficient to delay acceptance into ART clinics. Integrated
HIV and TB management to prioritise early initiation of ART,
with all TB and HIV components ideally managed by the same
clinic, may have more impact on the unsatisfactory scenario
reported here and the current focus on improving diagnostic
accuracy.
Table 4. Univariable and multivariable analysis of risk factors associated with TB diagnosis in HIV-negative participants.
TB cases/PYFU Unadjusted HR (95% CI) P Value Adjusted HR (95% CI) P Value
Overall (0–12 months) 34/415.4
Sex
Male 16/169.3 1.00 1.00
Female 18/246.0 0.79 (0.51 to 1.23) 0.301 0.82 (0.52 to 1.30) 0.403
Age (years)
,25–34 7/159.6{ 1.00 1.00
35–45 9/94.1 2.18 (0.92 to 5.13) 2.07 (0.88 to 4.89)
.45 18/161.6 2.56 (1.25 to 5.24) 0.033 2.47 (1.22 to 5.02) 0.040
Weight (kg)
0–59 19/167.5 2.45 (0.91 to 6.54)
60–69 10/135.6 1.61 (0.53 to 4.89)
.70 5/112.3 1.00 0.184
Previous TB treatment
No 28/381.3 1.00 1.00
Yes 6/34.1 2.42 (1.12 to 5.24) 0.024 2.18 (1.04 to 4.57) 0.039
{Age groups ,25 and 25–34 combined.
HR: hazard ratio; PYFU: person years follow-up; CI: confidence interval.
doi:10.1371/journal.pone.0011849.t004
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